Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients

Insulin has been used for diabetes therapy and has achieved significant therapeutic effect. In recent years, the use of purified and recombinant human insulin preparations has markedly reduced, but not completely suppressed, the incidence of insulin antibodies (IAs). IAs induced by exogenous insulin...

Full description

Saved in:
Bibliographic Details
Published inEndocrine Connections Vol. 7; no. 1; pp. R47 - R55
Main Authors Hu, Xiaolei, Chen, Fengling
Format Journal Article
LanguageEnglish
Published England Bioscientifica Ltd 01.01.2018
Bioscientifica
Subjects
diabetes
exogenous insulin antibody syndrome
hyperglycaemia
hypoglycaemia
insulin antibodies
Review
hyperglycaemia
insulin antibodies
hypoglycaemia
diabetes
exogenous insulin antibody syndrome
Online AccessGet full text

Cover

More Information
Summary:Insulin has been used for diabetes therapy and has achieved significant therapeutic effect. In recent years, the use of purified and recombinant human insulin preparations has markedly reduced, but not completely suppressed, the incidence of insulin antibodies (IAs). IAs induced by exogenous insulin in diabetic patients is associated with clinical events, which is named exogenous insulin antibody syndrome (EIAS). The present review is based on our research and summarizes the characterization of IAs, the factors affecting IA development, the clinical significance of IAs and the treatments for EIAS.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2049-3614
2049-3614
DOI:10.1530/EC-17-0309